| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B | Frank Vinluan | 11/25/19 | New York |
| As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing | Ben Fidler | 09/02/19 | New York |
| Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More | Alex Lash | 08/30/19 | National |
| New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.) | Alex Lash | 08/26/19 | National |
| Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark | Ben Fidler | 03/01/19 | National |
| 15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) | Ben Fidler | 12/18/18 | National |
| Regeneron to Slash Price of Cholesterol Drug After Showing It Saved Lives | Ben Fidler | 03/10/18 | New York |
| Esperion Touts Low Cholesterol Drug Price, But Not All Data are Ready | Alex Lash | 03/07/18 | Detroit Ann Arbor |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| Medicines Co. Sells Infectious Disease Drugs, Focusing on PCSK9 | David Holley | 11/29/17 | New York |
| Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing | Ben Fidler | 09/11/17 | New York |
| Will Merck Seek FDA Filing For Heart Drug After Lackluster Results? | Ben Fidler | 08/29/17 | New York |
| 70% Repatha Cut? Amgen Counters With Own Study To Justify Price | Alex Lash | 08/23/17 | National |
| Bio Roundup: $1B Deals, Data Bumps, Acorda’s Lumps, Generic OKs & More | Alex Lash | 08/11/17 | National |
| The Medicines Co., Alnylam Take Plunge, Outline Big Test For Heart Drug | Ben Fidler | 04/26/17 | New York |
| FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price | Alex Lash | 03/28/17 | New York |
| With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work | Ben Fidler | 03/17/17 | San Francisco |
| Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation | Alex Lash | 02/10/17 | National |
| Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins | Ben Fidler | 02/03/17 | National |
| No Details Yet, But Amgen Touts Success in Big Heart Drug Study | Ben Fidler | 02/02/17 | San Francisco |
| Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More | Ben Fidler | 01/13/17 | National |
| 14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/21/16 | National |
| Arrowhead’s Future Could Now Ride on Progress of Amgen Partnership | Jeff Buchanan | 11/30/16 | Wisconsin |
| With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 | Ben Fidler | 11/15/16 | New York |
| Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More | Alex Lash | 11/04/16 | National |
| Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More | Alex Lash | 09/02/16 | National |
| Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More | Alex Lash | 08/19/16 | National |
| Struggling Aegerion, QLT to Merge, Change Name to Novelion | Ben Fidler | 06/15/16 | Boston |
| Advisory Panel Backs Intercept’s Liver Drug, FDA Ruling up Next | Alex Lash | 04/07/16 | New York |
